{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:37:23Z","timestamp":1794947843016,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) and mixed dementia (MxD) represent major public health concerns, yet there is limited real-world evidence on the long-term associations of commonly prescribed pharmacological treatments, particularly cholinesterase inhibitors (ChEIs) and their combination with memantine. This study aims to evaluate the long-term, time-varying associations of ChEIs and memantine on cognitive decline in a large, nationwide cohort of individuals diagnosed with AD or MxD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational study utilized data from the Swedish registry for cognitive\/dementia disorders (SveDem), analyzing 32,282 individuals diagnosed with AD or MxD between 2007 and 2022. Patients were followed for up to 11 years to track treatment patterns and cognitive trajectories. Initiation of ChEIs (donepezil, galantamine, or rivastigmine) or memantine within six months after an AD or MxD diagnosis and then the time-varying medications (ChEIs alone, memantine alone or memantine added on to ChEIs) within six months after each follow-up were analyzed. Linear mixed-effects model was used to assess cognitive decline measured by Mini-Mental State Examination (MMSE) score trajectories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 32,282 participants (mean age 78.4 years; 61% women), 78.4% initiated treatment with ChEIs alone, and 21.6% with memantine alone. Over time, prescription patterns shifted from monotherapy to combination therapy, with donepezil and galantamine more likely to achieve 1 Defined Daily Dosages (DDD) than rivastigmine users. Memantine alone users experienced a yearly cognitive decline of 1.79 MMSE points (95% CI: \u22121.85, \u22121.73). Compared with memantine users, patients on ChEIs alone declined 0.65 points less per year (95% CI: \u22120.59, \u22120.72), while those on combination therapy declined 0.19 points less per year (95% CI: \u22120.10, \u22120.28). Among ChEIs, donepezil users experienced an annual decline of 1.02 points (95% CI: \u22121.06, \u22120.98). In comparison, galantamine users declined an additional 0.05 points per year (95% CI: \u22120.11, 0.01), and rivastigmine users declined an additional 0.17 points per year (95% CI: \u22120.24, \u22120.11), relative to donepezil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large cohort of patients with AD or MxD, ChEIs users alone, particularly donepezil and galantamine, showed slower cognitive decline compared to users of memantine or combination therapy users. While differences were modest, the results contribute to a better understanding of treatment trajectories in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-025-01918-0","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:44:58Z","timestamp":1764319498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dynamic associations of cholinesterase inhibitors and memantine with cognitive trajectories in individuals with Alzheimer\u2019s or mixed dementia: a real-world analysis using the quality registry SveDem"],"prefix":"10.1186","volume":"17","author":[{"given":"Cen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjia","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"\u00c5kerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Garcia-Ptacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Eriksdotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"1","key":"1918_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","volume":"18","author":"Collaborators GBDD","year":"2019","unstructured":"Collaborators GBDD. Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88\u2013106. https:\/\/doi.org\/10.1016\/S1474-4422(18)30403-4.","journal-title":"Lancet Neurol"},{"key":"1918_CR2","doi-asserted-by":"publisher","unstructured":"2023 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. Apr 2023;19(4):1598\u20131695. https:\/\/doi.org\/10.1002\/alz.13016.","DOI":"10.1002\/alz.13016"},{"issue":"5","key":"1918_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1001\/jamainternmed.2023.8522","volume":"184","author":"DB Reuben","year":"2024","unstructured":"Reuben DB, Kremen S, Maust DT. Dementia prevention and treatment: a narrative review. JAMA Intern Med. 2024;184(5):563. https:\/\/doi.org\/10.1001\/jamainternmed.2023.8522.","journal-title":"JAMA Intern Med"},{"issue":"11","key":"1918_CR4","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1093\/brain\/aww224","volume":"139","author":"BD James","year":"2016","unstructured":"James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer\u2019s-type dementia. Brain. 2016;139(11):2983\u201393. https:\/\/doi.org\/10.1093\/brain\/aww224.","journal-title":"Brain"},{"issue":"1","key":"1918_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005593","volume":"25","author":"J Birks","year":"2006","unstructured":"Birks J. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev Jan. 2006;25(1):CD005593. https:\/\/doi.org\/10.1002\/14651858.CD005593.","journal-title":"Cochrane Database Syst Rev Jan"},{"issue":"9427","key":"1918_CR6","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","volume":"26","author":"C Courtney","year":"2004","unstructured":"Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with alzheimer\u2019s disease (AD2000): randomised double-blind trial. Lancet Jun. 2004;26(9427):2105\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(04)16499-4.","journal-title":"Lancet Jun"},{"issue":"3\u20134","key":"1918_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000486546","volume":"45","author":"R Knight","year":"2018","unstructured":"Knight R, Khondoker M, Magill N, Stewart R, Landau S. A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dement Geriatr Cogn Disord. 2018;45(3\u20134):131\u201351. https:\/\/doi.org\/10.1159\/000486546.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"1918_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0457-9","volume":"10","author":"KX Dou","year":"2018","unstructured":"Dou KX, Tan MS, Tan CC. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer\u2019s disease: a network meta-analysis of 41 randomized controlled trials. Alzheimers Res Ther. 2018;10(1):126. https:\/\/doi.org\/10.1186\/s13195-018-0457-9.","journal-title":"Alzheimers Res Ther"},{"issue":"9314","key":"1918_CR9","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","volume":"359","author":"T Erkinjuntti","year":"2002","unstructured":"Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359(9314):1283. https:\/\/doi.org\/10.1016\/S0140-6736(02)08267-3.","journal-title":"Lancet"},{"issue":"9","key":"1918_CR10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","volume":"6","author":"H Kavirajan","year":"2007","unstructured":"Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6(9):782\u201392. https:\/\/doi.org\/10.1016\/S1474-4422(07)70195-3.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1918_CR11","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.archger.2008.07.006","volume":"49","author":"M Calabria","year":"2009","unstructured":"Calabria M, Geroldi C, Lussignoli G, Sabbatini F, Zanetti O. Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer\u2019s disease: a 21-month follow-up \u201creal world\u201d study. Arch Gerontol Geriatr. 2009;49(1):e6-11. https:\/\/doi.org\/10.1016\/j.archger.2008.07.006.","journal-title":"Arch Gerontol Geriatr"},{"issue":"8","key":"1918_CR12","doi-asserted-by":"publisher","first-page":"902","DOI":"10.2174\/156720512803251066","volume":"9","author":"B Vellas","year":"2012","unstructured":"Vellas B, Hausner L, Frolich L, et al. Progression of Alzheimer disease in Europe: data from the European ICTUS study. Curr Alzheimer Res. 2012;9(8):902\u201312. https:\/\/doi.org\/10.2174\/156720512803251066.","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"1918_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000098052","volume":"23","author":"\u00c5K Wallin","year":"2007","unstructured":"Wallin \u00c5K, Andreasen N, Eriksson S, et al. Donepezil in Alzheimer\u2019s disease:: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord. 2007;23(3):150\u201360. https:\/\/doi.org\/10.1159\/000098052.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"5\u20136","key":"1918_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000437050","volume":"40","author":"C Wattmo","year":"2015","unstructured":"Wattmo C, Londos E, Minthon L. Longitudinal associations between survival in Alzheimer\u2019s disease and cholinesterase inhibitor use, progression, and community-based services. Dement Geriatr Cogn Disord. 2015;40(5\u20136):297\u2013310. https:\/\/doi.org\/10.1159\/000437050.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"17","key":"1918_CR15","doi-asserted-by":"publisher","first-page":"e2220","DOI":"10.1212\/WNL.0000000000011832","volume":"27","author":"H Xu","year":"2021","unstructured":"Xu H, Garcia-Ptacek S, Jonsson L, Wimo A, Nordstrom P, Eriksdotter M. Long-term effects of cholinesterase inhibitors on cognitive decline and mortality. Neurology. 2021;27(17):e2220-30. https:\/\/doi.org\/10.1212\/WNL.0000000000011832.","journal-title":"Neurology"},{"key":"1918_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14118","author":"H Xu","year":"2024","unstructured":"Xu H, Habich A, Ferreira D, Elisabet L, Westman E, Eriksdotter M. Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: an up to 10-year follow-up study. Alzheimers Dement. 2024. https:\/\/doi.org\/10.1002\/alz.14118.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"1918_CR17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1185\/030079905X56565","volume":"21","author":"R Bullock","year":"2005","unstructured":"Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer\u2019s disease over a 2-year period. Curr Med Res Opin. 2005;21(8):1317\u201327. https:\/\/doi.org\/10.1185\/030079905X56565.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"1918_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-015-0109-2","volume":"7","author":"A Atri","year":"2015","unstructured":"Atri A, Hendrix SB, Pejovic V, Hofbauer RK, Edwards J, Molinuevo JL, et al. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer\u2019s dementia: a pooled area under the curve analysis. Alzheimers Res Ther. 2015;7(1):28. https:\/\/doi.org\/10.1186\/s13195-015-0109-2.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1918_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"issue":"6","key":"1918_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"key":"1918_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/CLEP.S282475","volume":"13","author":"JF Ludvigsson","year":"2021","unstructured":"Ludvigsson JF, Appelros P, Askling J, et al. Adaptation of the Charlson Comorbidity Index for register-based research in Sweden. Clin Epidemiol. 2021;13:21\u201341. https:\/\/doi.org\/10.2147\/CLEP.S282475.","journal-title":"Clin Epidemiol"},{"key":"1918_CR22","unstructured":"Methodology WCCfDS. ATC\/DDD Index. 2024. Norwegian Institute of public health. https:\/\/atcddd.fhi.no\/atc_ddd_index\/. Accessed 26 01 2024."},{"issue":"7","key":"1918_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4080","volume":"1","author":"RE Kennedy","year":"2018","unstructured":"Kennedy RE, Cutter GR, Fowler ME, Schneider LS. Association of concomitant use of cholinesterase inhibitors or memantine with cognitive decline in Alzheimer clinical trials: a meta-analysis. JAMA Netw Open. 2018;1(7):e184080. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.4080.","journal-title":"JAMA Netw Open"},{"key":"1918_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093272","author":"MT Kabir","year":"2020","unstructured":"Kabir MT, Uddin MS, Mamun AA, et al. Combination drug therapy for the management of Alzheimer\u2019s disease. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21093272.","journal-title":"Int J Mol Sci"},{"key":"1918_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108352","volume":"190","author":"G Marucci","year":"2021","unstructured":"Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Neuropharmacology. 2021;190:108352. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108352.","journal-title":"Neuropharmacology"},{"issue":"2","key":"1918_CR26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1742-1241.2009.02253.x","volume":"64","author":"CH Sadowsky","year":"2010","unstructured":"Sadowsky CH, Farlow MR, Meng X, Olin JT. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. Int J Clin Pract. 2010;64(2):188\u201393. https:\/\/doi.org\/10.1111\/j.1742-1241.2009.02253.x.","journal-title":"Int J Clin Pract"},{"issue":"7","key":"1918_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2165\/11591860-000000000-00000","volume":"28","author":"L Patel","year":"2011","unstructured":"Patel L, Grossberg GT. Combination therapy for Alzheimer\u2019s disease. Drugs Aging. 2011;28(7):539\u201346. https:\/\/doi.org\/10.2165\/11591860-000000000-00000.","journal-title":"Drugs Aging"},{"issue":"3","key":"1918_CR28","doi-asserted-by":"publisher","first-page":"CD003154","DOI":"10.1002\/14651858.CD003154.pub6","volume":"20","author":"R McShane","year":"2019","unstructured":"McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev Mar. 2019;20(3):CD003154. https:\/\/doi.org\/10.1002\/14651858.CD003154.pub6.","journal-title":"Cochrane Database Syst Rev Mar"},{"issue":"14","key":"1918_CR29","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s00213-017-4616-7","volume":"234","author":"T Kishi","year":"2017","unstructured":"Kishi T, Matsuda Y, Iwata N. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. Psychopharmacology (Berl). 2017;234(14):2113\u201325. https:\/\/doi.org\/10.1007\/s00213-017-4616-7.","journal-title":"Psychopharmacology (Berl)"},{"issue":"10","key":"1918_CR30","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2165\/00003088-200241100-00003","volume":"41","author":"MW Jann","year":"2002","unstructured":"Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002;41(10):719\u201339. https:\/\/doi.org\/10.2165\/00003088-200241100-00003.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1918_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/156720510790274455","volume":"7","author":"T Darreh-Shori","year":"2010","unstructured":"Darreh-Shori T, Soininen H. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer\u2019s disease: a review of recent clinical studies. Curr Alzheimer Res. 2010;7(1):67\u201373. https:\/\/doi.org\/10.2174\/156720510790274455.","journal-title":"Curr Alzheimer Res"},{"key":"1918_CR32","unstructured":"Clinic M. Rivastigmine (oral route). https:\/\/www.mayoclinic.org\/drugs-supplements\/rivastigmine-oral-route\/description\/drg-20065860. Accessed 5 Nov."},{"issue":"11","key":"1918_CR33","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1185\/030079907x233403","volume":"23","author":"G Small","year":"2007","unstructured":"Small G, Dubois B. A review of compliance to treatment in Alzheimer\u2019s disease: potential benefits of a transdermal patch. Curr Med Res Opin. 2007;23(11):2705\u201313. https:\/\/doi.org\/10.1185\/030079907x233403.","journal-title":"Curr Med Res Opin"},{"key":"1918_CR34","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3389\/fnins.2019.00472","volume":"13","author":"DD Li","year":"2019","unstructured":"Li DD, Zhang YH, Zhang W, Zhao P. Meta-analysis of randomized controlled trials on the efficacy and safety of Donepezil, Galantamine, Rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease. Front Neurosci. 2019;13:472. https:\/\/doi.org\/10.3389\/fnins.2019.00472.","journal-title":"Front Neurosci"},{"issue":"14","key":"1918_CR35","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg B, Doody R, St\u00f6ffler A, Schmitt F, Ferris S, M\u00f6bius HJ. Memantine in moderate-to-severe Alzheimer\u2019s disease. N Engl J Med. 2003;348(14):1333\u201341. https:\/\/doi.org\/10.1056\/NEJMoa013128.","journal-title":"N Engl J Med"},{"issue":"6","key":"1918_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2023.11703","volume":"330","author":"GD Rabinovici","year":"2023","unstructured":"Rabinovici GD, La Joie R. Amyloid-targeting monoclonal antibodies for Alzheimer disease. JAMA. 2023;330(6):507\u20139. https:\/\/doi.org\/10.1001\/jama.2023.11703.","journal-title":"JAMA"},{"issue":"15","key":"1918_CR37","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jama.2023.14443","volume":"330","author":"R Rubin","year":"2023","unstructured":"Rubin R. Who should-and can-get Lecanemab, the new Alzheimer disease drug? JAMA. 2023;330(15):1411\u20135. https:\/\/doi.org\/10.1001\/jama.2023.14443.","journal-title":"JAMA"},{"issue":"9","key":"1918_CR38","doi-asserted-by":"publisher","first-page":"6659","DOI":"10.1002\/alz.14114","volume":"20","author":"T Daly","year":"2024","unstructured":"Daly T, Kepp KP, Imbimbo BP. Are lecanemab and donanemab disease-modifying therapies? Alzheimers Dement. 2024;20(9):6659\u201361. https:\/\/doi.org\/10.1002\/alz.14114.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"1918_CR39","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1212\/wnl.0000000000008745","volume":"94","author":"ML Haaksma","year":"2020","unstructured":"Haaksma ML, Eriksdotter M, Rizzuto D, Leoutsakos JS, Olde Rikkert MGM, Melis RJF, et al. Survival time tool to guide care planning in people with dementia. Neurology. 2020;94(5):e538\u201348. https:\/\/doi.org\/10.1212\/wnl.0000000000008745.","journal-title":"Neurology"},{"issue":"1","key":"1918_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/ebmed-2017-110883","volume":"23","author":"D Nunan","year":"2018","unstructured":"Nunan D, Aronson J, Bankhead C. Catalogue of bias: attrition bias. BMJ Evid Based Med. 2018;23(1):21\u20132. https:\/\/doi.org\/10.1136\/ebmed-2017-110883.","journal-title":"BMJ Evid Based Med"},{"issue":"2","key":"1918_CR41","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/biom.13321","volume":"77","author":"L Wen","year":"2021","unstructured":"Wen L, Young JG, Robins JM, Hernan MA. Parametric g-formula implementations for causal survival analyses. Biometrics. 2021;77(2):740\u201353. https:\/\/doi.org\/10.1111\/biom.13321.","journal-title":"Biometrics"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01918-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01918-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01918-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:03:41Z","timestamp":1781618621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-025-01918-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1918"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01918-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data were extracted anonymized from electronic records. The Swedish Ethical Review Authority waived patient consent for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"ME has served as speaker and\/or consultant on dementia on sporadic advisory board meetings for Biogen, Bioarctic, Roche, Eli Lilly and NovoNordisk. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"ME has served as speaker and\/or consultant on dementia on sporadic advisory board meetings for Biogen, Bioarctic, Roche, Eli Lilly and NovoNordisk. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"256"}}